Safety tool
Peptide Interaction Checker
Pick 2 – 5 research peptides and the checker returns the pairwise interaction matrix with severity labels — caution, warning, or avoid — drawn from documented co-administration research.
Choose peptides (2 – 5)
Selections are checked pairwise against the documented research-stage interactions dataset.
Results
Avoid: One or more selected pairs are not co-investigated in research literature.
- Semaglutide + Tirzepatideavoid
Both are long-acting incretin-class agents; stacking compounds gastric and metabolic effects.
Severity bands
- Clear — no documented pairwise concern in the current dataset.
- Caution — frequently co-investigated; design the protocol to attribute effects cleanly.
- Warning — overlapping mechanism; combination is rarely studied or carries known additive effects.
- Avoid — the combination is not co-investigated in published research-stage protocols.
How the dataset is built
Each pairwise entry references either a published research-stage co-administration study, a shared receptor mechanism, or guidance from manufacturer monographs. Entries are symmetric (A + B == B + A) and the worst-severity finding is surfaced as the overall stack signal.
Related tools
- Stack Builder — bundles this checker with a weekly schedule.
- Protocol Simulator — multi-week timeline.
Frequently asked questions
How does the peptide interaction checker work?
The checker iterates pairwise across the peptides you select and looks each pair up in the documented interaction dataset. Each entry is rated caution, warning or avoid, with a short reason citing the underlying mechanism overlap or literature gap.
What does an "avoid" rating mean for a peptide pair?
An "avoid" rating means the combination is not co-investigated in published research-stage protocols and combining them exceeds documented safety envelopes. Common examples are two GLP-1 agonists or two GHRH analogs in the same week.
Are "caution" ratings unsafe?
No — "caution" usually means the pair is frequently co-investigated and the rating exists so you can design the protocol to attribute effects cleanly (for example by staggering the introduction by at least one half-life of the first peptide).
Why is the CJC-1295 + Ipamorelin pair only rated "caution" despite both targeting GH release?
CJC-1295 is a GHRH analog and Ipamorelin is a ghrelin-mimetic GHRP — they act on different receptors with synergistic downstream signalling. This is one of the most studied research-stage stacks in the GH axis.
How often is the interaction dataset updated?
The dataset is reviewed against new research-stage literature each editorial cycle. Pairwise entries cite either a co-administration study, a shared receptor mechanism, or a manufacturer monograph; the worst-severity finding for any selection drives the overall stack signal.